- Advanced search
|International Nonproprietary Names|
|Search PubMed clinical trials||racotumomab|
|Search PubMed titles||racotumomab|
|Search PubMed titles/abstracts||racotumomab|
|Racotumomab is an anti-idiotype therapeutic cancer vaccine directed against the ganglioside N-glycolil (NGc) GM3, which has been identified on the cell surface of malignant cells from lung  and breast tumours , melanoma [8-9], and neuroectodermal pediatric tumours [4-5,10-11]. Racotumomab is being investigated for its antineoplastic activity.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.